Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Patel Nishitkumar Maheshbhai Updates
Lincoln Pharmaceuticals Ltd has submitted to BSE a copy of Newspaper Advertisement of the Notice Published in the Newspaper on December 12, 2016 in respect of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Suspense Account in pursuant of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. Lincoln Pharma delists from Ahmedabad Stock Exchange
Lincoln Pharmaceuticals has delisted its shares from Ahmedabad Stock Exchange Ltd.Pursuant to the application made by the company to ASEL for voluntary delisting of its equity shares, ASEL has... Delisting of Equity Shares from Ahmedabad Stock Exchange Limited (ASEL)
Lincoln Pharmaceuticals Ltd has informed BSE that pursuant to the application made by the Company to ASEL for voluntary delisting of its Equity shares as per the provision of SEBI (Delisting of Equity Shares) Regulations, 2009. ASEL has vide its letter dated November 23, 2016 granted the approval for delisting of Equity Shares of the Company and accordingly the Equity shares of the company stand de-listed from ASEL with effect from November 24, 2016. Outcome of Board Meeting
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at their meeting held on November 10, 2016, had considered and approved the following:- The proposal of Delisting of Equity Shares of the Company from Ahmedabad Stock Exchange Limited pursuant to SEBI (Delisting of Equity Shares) Regulations, 2009 as amended from time to time. Standalone & Consolidated Financial Results, Limited Review Report for September 30, 2016
Lincoln Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Consolidated Financial Results for the period ended September 30, 20163. Standalone Limited Review for the period ended September 30, 20164. Consolidated Limited Review for the period ended September 30, 2016 Shareholding for the Period Ended October 27, 2016
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended October 27, 2016. For more details, kindly Click here Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Lincoln Pharmaceuticals Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Outcome of Board Meeting
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at their meeting held on October 27, 2016 have considered and approved, issue and allotment of 36,89,200 Equity Shares to the Warrant holders belonging to Promoter/Promoter Group and Non-Promoter Group on account of exercise of their right of Conversion of Warrants into Equity Shares at an exercise price of Rs. 82/- Per Share.The Board Meeting commenced at 10:30 A.M. and concluded at 11:15 A.M. Board Meeting on Nov 10, 2016
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on November 10, 2016, to consider and approve the following:1. Un-audited Consolidated and Standalone Financial Results of the Company for the Quarter and half year ended on September 30, 2016.2. Delisting of Equity Shares of the Company from Ahmedabad Stock Exchange Limited pursuant to SEBI (Delisting of...